| Latest Xtl Biopharmaceuticals Ltd News Headlines |
| Date | Time | Source | |
| 07/20/2008 | 10:27AM | PRNUS | AGM / EGM Statements
VALLEY COTTAGE, N.Y., July 20 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announces the results of its Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") held earlier today.
The outcome of the AGM was as follows: all of the resolutions passed and the existing... More...>> |
| 07/17/2008 | 11:10AM | PRNUS | AGM / EGM Postponed to July 20, 2008
VALLEY COTTAGE, N.Y., July 17 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announces that the Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") scheduled for today were adjourned and postponed until Sunday, July 20, 2008 at 4:00pm and 4:30 pm Israel time, respectively.
ABOUT... More...>> |
| 07/01/2008 | 10:00AM | PRNUS | BeaconEquity.com Issues TraderNotes on Active Stocks: ORRV, XTLB, SHFL, CWSI, HRB, GVHR, TCHC, ORCL
DALLAS, July 1 /PRNewswire-FirstCall/ -- BeaconEquity.com announces the availability of TraderNotes on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's TraderNotes include: Oceanic Research and Recovery Inc. (Pink Sheets: ORRV... More...>> |
| 06/30/2008 | 7:35AM | PRNUS | XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatme
VALLEY COTTAGE, N.Y., June 30 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced that it has completed patient randomization into its Phase 2b study of Bicifadine -- a serotonin and norepinephrine reuptake inhibitor (SNRI) -- for the treatment of diabetic neuropathic pain... More...>> |
| 06/12/2008 | 12:46PM | PRNUS | Notification of Record Date for the Annual General Meeting and Extraordinary General Meeting
VALLEY COTTAGE, New York, June 12 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced that the record date for its Annual General Meeting and Extraordinary General Meeting (collectively, the "Meetings") scheduled for July 17, 2008, is hereby amended so that shareholders of record... More...>> |
| 06/11/2008 | 5:50PM | PRNUS | Notification of Annual General Meeting and Extraordinary General Meeting
VALLEY COTTAGE, New York, June 11 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced a notice convening its Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM"). The AGM and EGM will take place at the Conference Room at the Company's Israeli offices at Building... More...>> |
| 05/28/2008 | 7:35AM | PRNUS | XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
VALLEY COTTAGE, N.Y., May 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced that Laurence N. Charney, CPA, has been appointed to XTL's Board of Directors. The appointment, effective immediately, increases the size of XTL's Board to six members.
Mr. Charney, 61, recently... More...>> |
| 05/15/2008 | 7:35AM | PRNUS | XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
VALLEY COTTAGE, N.Y., May 15 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 5th Annual Global Healthcare Conference. Mr. Bentsur will present an overview of the Company... More...>> |
| 03/20/2008 | 5:15PM | PRNUS | XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
VALLEY COTTAGE, N.Y., March 20 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL), a biopharmaceutical company engaged in the acquisition and development of therapeutics for the treatment of unmet medical needs, particularly diabetic neuropathic pain and hepatitis C, today announced its financial... More...>> |
| 03/20/2008 | 7:35AM | PRNUS | XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmac
VALLEY COTTAGE, N.Y., March 20 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) announced the licensing of its pre-clinical program in Hepatitis C focused on the NS5A target (the "Program") to San-Francisco based Presidio Pharmaceuticals, Inc. Presidio is a private biotechnology... More...>> |
| 02/07/2008 | 7:35AM | PRNUS | XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
VALLEY COTTAGE, N.Y., Feb. 7 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the 10th Annual BIO CEO & Investor Conference. Mr. Bentsur will present an overview of the Company including a... More...>> |
| 01/07/2008 | 9:35AM | PRNUS | XTL Biopharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference
VALLEY COTTAGE, N.Y., Jan. 7 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the 26th Annual JPMorgan Healthcare Conference. Mr. Bentsur will present an overview of the Company including... More...>> |
| 01/07/2008 | 7:30AM | PRNUS | XTL Biopharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference
VALLEY COTTAGE, N.Y., Jan. 7 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the 26th Annual JPMorgan Healthcare Conference. Mr. Bentsur will present an overview of the Company including... More...>> |
| 12/10/2007 | 7:00AM | PRNUS | XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International
VALLEY COTTAGE, N.Y., Dec. 10 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) announced today that it will make two scientific presentations related to its pre-clinical Hepatitis C virus (HCV) small molecule program at HEP DART 2007, an international scientific conference on... More...>> |
| 10/31/2007 | 7:43AM | PRNUS | XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
Processing Fees on Transfer of Ordinary Shares Into ADRs to be Waived for an Additional Month
VALLEY COTTAGE, New York, October 31 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced that the Company's ordinary shares have been delisted from the Official List of the United Kingdom... More...>> |
| 10/29/2007 | 5:09AM | PRNUS | XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care Conference
NEW YORK, October 29 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Acumen BioFin Rodman & Renshaw 9th Annual Health Care Conference. Mr. Bentsur will present an overview of... More...>> |
| 10/25/2007 | 10:42AM | PRNUS | XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
NEW YORK, October 25 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) today announced that it has entered into definitive agreements with institutional investors relating to a private placement of an aggregate of $9.6 million in gross proceeds of ordinary shares, represented by... More...>> |
| 10/02/2007 | 12:07PM | PRNUS | XTL Biopharmaceuticals: AGM/EGM Statements
VALLEY COTTAGE, New York, October 2 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announces today that at its Annual General Meeting and Extraordinary General Meeting held earlier today, all the resolutions proposed to the shareholders were approved.
The cancellation of the... More...>> |
| 09/26/2007 | 3:55AM | PRNUS | XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
VALLEY COTTAGE, New York, September 26 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) today announced that on September 24, 2007, the Company received a NASDAQ Staff Determination indicating that the Company fails to comply with the minimum $10 million shareholders' equity requirement... More...>> |
| 09/25/2007 | 12:12PM | PRNUS | XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
VALLEY COTTAGE, New York, September 25 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announces today that its Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") was postponed for one week in accordance with its articles of association due to the absence... More...>> |